TNGX vs. EBS

Last updated Apr 2, 2026

Compare and contrast key facts about Tango Therapeutics, Inc. (TNGX) and Emergent BioSolutions Inc. (EBS).

Performance

TNGX vs. EBS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tango Therapeutics, Inc. (TNGX) and Emergent BioSolutions Inc. (EBS). The values are adjusted to include any dividend payments, if applicable.

TNGX vs. EBS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
TNGX Tango Therapeutics, Inc.	139.50%	186.73%	-68.79%	36.55%	-33.73%	-4.37%	11.83%
EBS Emergent BioSolutions Inc.	-32.20%	29.29%	298.33%	-79.68%	-72.83%	-51.48%	-16.24%

Fundamentals

Market Cap TNGX : $2.47B EBS : $475.15M
EPS TNGX : -$0.90 EBS : $0.94
PS Ratio TNGX : 38.29 EBS : 0.63
PB Ratio TNGX : 7.12 EBS : 0.91
Total Revenue (TTM) TNGX : $62.38M EBS : $742.90M
Gross Profit (TTM) TNGX : $61.20M EBS : $0.00
EBITDA (TTM) TNGX : -$105.54M EBS : $271.60M

Returns By Period

In the year-to-date period, TNGX achieves a 139.50% return, which is significantly higher than EBS's -32.20% return.

TNGX

• 1D: 1.43%
• 1M: 84.04%
• YTD: 139.50%
• 6M: 166.08%
• 1Y: 1,557.81%
• 3Y*: 75.14%
• 5Y*: 14.09%
• 10Y*: —

EBS

• 1D: 0.96%
• 1M: -6.79%
• YTD: -32.20%
• 6M: -8.81%
• 1Y: 76.79%
• 3Y*: -6.83%
• 5Y*: -36.39%
• 10Y*: -13.20%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TNGX vs. EBS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TNGX

TNGX Risk / Return Rank: 100
TNGX Sharpe Ratio Rank: 100
TNGX Sortino Ratio Rank: 99
TNGX Omega Ratio Rank: 99
TNGX Calmar Ratio Rank: 100
TNGX Martin Ratio Rank: 100

EBS

EBS Risk / Return Rank: 73
EBS Sharpe Ratio Rank: 68
EBS Sortino Ratio Rank: 76
EBS Omega Ratio Rank: 76
EBS Calmar Ratio Rank: 72
EBS Martin Ratio Rank: 73

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TNGX vs. EBS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tango Therapeutics, Inc. (TNGX) and Emergent BioSolutions Inc. (EBS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TNGX	EBS	Difference
Sharpe ratio Return per unit of total volatility	14.19	0.83	+13.36
Sortino ratio Return per unit of downside risk	7.27	1.94	+5.33
Omega ratio Gain probability vs. loss probability	1.87	1.26	+0.61
Calmar ratio Return relative to maximum drawdown	53.36	1.69	+51.68
Martin ratio Return relative to average drawdown	149.92	4.27	+145.64
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TNGX vs. EBS - Sharpe Ratio Comparison

The current TNGX Sharpe Ratio is 14.19, which is higher than the EBS Sharpe Ratio of 0.83. The chart below compares the historical Sharpe Ratios of TNGX and EBS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TNGX	EBS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	14.19	0.83	+13.36
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.14	-0.36	+0.50
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.17	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.15	-0.02	+0.17

Correlation

The correlation between TNGX and EBS is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TNGX vs. EBS - Dividend Comparison

Neither TNGX nor EBS has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
TNGX Tango Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBS Emergent BioSolutions Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5.65%

Drawdowns

TNGX vs. EBS - Drawdown Comparison

The maximum TNGX drawdown since its inception was -93.64%, smaller than the maximum EBS drawdown of -98.89%. Use the drawdown chart below to compare losses from any high point for TNGX and EBS.

Drawdown Indicators

	TNGX	EBS	Difference
Max Drawdown Largest peak-to-trough decline	-93.64%	-98.89%	+5.25%
Max Drawdown (1Y) Largest decline over 1 year	-27.15%	-42.95%	+15.80%
Max Drawdown (5Y) Largest decline over 5 years	-93.64%	-98.14%	+4.50%
Max Drawdown (10Y) Largest decline over 10 years	—	-98.89%	—
Current Drawdown Current decline from peak	0.00%	-93.79%	+93.79%
Average Drawdown Average peak-to-trough decline	-49.26%	-40.60%	-8.66%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.66%	16.95%	-7.29%

Volatility

TNGX vs. EBS - Volatility Comparison

Tango Therapeutics, Inc. (TNGX) has a higher volatility of 33.39% compared to Emergent BioSolutions Inc. (EBS) at 9.05%. This indicates that TNGX's price experiences larger fluctuations and is considered to be riskier than EBS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TNGX	EBS	Difference
Volatility (1M) Calculated over the trailing 1-month period	33.39%	9.05%	+24.34%
Volatility (6M) Calculated over the trailing 6-month period	63.25%	61.33%	+1.92%
Volatility (1Y) Calculated over the trailing 1-year period	111.38%	93.41%	+17.97%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	98.22%	102.08%	-3.86%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	93.68%	79.69%	+13.99%

Financials